Blog - Page 792 of 5695 - QualityStocks

FridayJan 13, 2023 11:15 am

Health Equity In Clinical Trials Congress To Encourage Cross-Industry Networking and Expansion of Diversity and Equity

Professionals and executives from the biopharma, health organizations, CROs, Digital Solutions, Policy Developers, and Medical Device Companies, are invited to attend the Health Equity In Clinical Trials Congress being held in Boston, February 22-23, 2023. Participants will get access to a wide spectrum of healthcare opportunities and the chance to meet and connect with veterans of the industry. In the two main event days, 25+ leading industry speakers will gather on this forum to share their valuable insights in 5 keynote sessions, and will discuss tactful approaches to drive meaningful change for underrepresented communities through meaningful cross-industry networks and scaling…

FridayJan 13, 2023 10:30 am

QualityStocksNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) CEO Reports on Company Accomplishments, Outlook through Shareholder Letter

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and NFTs, and JUPW’s SRM Entertainment division submitting a confidential registration statement to the SEC on a key step on its journey to becoming an independently traded NASDAQ company. The letter also noted that Jupiter Wellness…

FridayJan 13, 2023 10:30 am

REZYFi, Inc. Creates Opportunities for Cannabis Related Real Estate Financing as Mainstream Media Begins to Show Growing Acceptance of Cannabis-Derived Products

Google will change its requirements for product ads on January 20, 2023, to allow the promotion of FDA-approved pharmaceuticals containing CBD and topical hemp-derived CBD products in California, Colorado, and Puerto Rico Non-FDA-approved CBD topicals will require certification from LegitScript, which will test THC compliance and review the third-party Certificate of Analysis of each product to be promoted With the growing acceptance of cannabis, REZYFi is positioned in the financial industry as one of the first cannabis mortgage bankers in the United States In the United States, cannabis-related products are growing in acceptance, even in mainstream media. A recent announcement…

FridayJan 13, 2023 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes The company has since expanded the device’s…

FridayJan 13, 2023 9:30 am

QualityStocksNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) CEO Featured on Gamechangers LIVE(R)

Cerberus Sentinel (NASDAQ: CISO) founder and CEO David Jemmett was featured on a recent episode of Gamechangers LIVE(R) with host Sergio Tigera. The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspectives on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. In the episode, Jemmett discusses his extensive background in the field and the origins of Cerberus Sentinel, an industry leader in cybersecurity and compliance services that leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. “If…

ThursdayJan 12, 2023 2:28 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

ThursdayJan 12, 2023 2:18 pm

QualityStocksNewsBreaks – Coyuchi Inc. Positioned to Propel Its New Growth Phase

Coyuchi is setting the gold standard in sustainable luxury home goods, offering organic bedding, sheets, towels, apparel, and more for the environmentally conscious home. “For 30 years, Coyuchi has explored organic farming and sustainable textiles, and guarantees the highest environmental and ethical standards through its acquisition of certifications, including the Global Organic Textile Standard (‘GOTS’), Fair Trade Certified, and MADE SAFE(R). Backed by a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base driving the fast-growing organic luxury market, Coyuchi is positioned to propel its new growth phase as the world awakens to sustainability at scale,”…

ThursdayJan 12, 2023 1:10 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian Medical University (“PUM”) in Szczecin, Poland. “Based on the data seen to date, Berubicin has continued to demonstrate an overall safety profile more favorable than other known anthracyclines and we remain encouraged by its potential.…

ThursdayJan 12, 2023 12:46 pm

QualityStocksNewsBreaks – Vision Energy Corp. (VENG) Issues Update on Recent Market Activity

Vision Energy (OTC: VENG) (the “Company”) today issued statements regarding recent removal from the OTCQB Market. On Dec. 6, 2022, Vision Energy was informed by the OTC Markets Group Inc. of certain promotional material that encouraged investors to purchase or trade the Company’s common stock. On Jan. 10, 2022, the Company was informed that, due to the ongoing promotional campaign, it would be moved from the OTCQB Market to the Pink Market effective Jan. 11, 2023. As detailed in the update, Vision Energy is and continues to be committed to compliance with OTC Markets’ policy on stock promotion and the…

Site Search

Company Search